Article Text

PDF
Survival outcomes of primary cutaneous T-cell lymphoma in HIV-infected patients: a national population-based study
  1. Jianhong Wang,
  2. Rong Liang,
  3. Caixia Hao,
  4. Xiangxiang Liu,
  5. Na Zhang,
  6. Xiaohui Duan,
  7. Hongjuan Dong,
  8. Baoxia Dong,
  9. Hongtao Gu,
  10. Guangxun Gao,
  11. Tao Zhang,
  12. Qingxian Bai,
  13. Xiequn Chen
  1. Department of Hematology, Xijing Hosptial, Fourth Military Medical University, Xi’an, China
  1. Correspondence to Dr Rong Liang, Department of Hematology, Xijing Hosptial, Fourth Military Medical University, Xi’an 710032, China; rongliang1017{at}yahoo.com

Abstract

This study aimed to investigate clinical characteristics and survival outcomes of primary cutaneous T-cell lymphoma (CTCL) in HIV-infected and non-HIV-infected patients. All data were from the Surveillance, Epidemiology, and End Results program, 1973–2013, of the U.S. National Cancer Institute. Data of 318 HIV-infected patients and 1272 non-HIV-infected patients with primary CTCL were analyzed. Endpoints were overall survival and cancer-specific mortality. Independent variables included demographics, pre-existing malignancy, treatments, and environmental factors. Among 8823 patients with CTCL, 318 (3.60 per cent) were HIV-infected and 8505 (96.40 per cent) were not. 318 HIV-infected patients and 1272 non-HIV-infected patients selected by matching diagnosis dates were analyzed, including 941 (59.2 per cent) males and 649 (40.8 per cent) females with mean age 58.8 years. HIV-infected patients with CTCL had higher survival and significantly lower risk of overall mortality than non-HIV-infected patients (adjusted HR 0.37, 95 per cent CI 0.24 to 0.59, P<0.001). Non-HIV-infected, age and black race were significant risk factors for overall mortality. Age and race are independent risk factors for overall mortality in primary CTCL individuals, and HIV-infected status is an independent protective factor, suggesting that advanced antiretroviral therapy restores immunity and prolongs survival in HIV-infected patients with CTCL.

  • primary cutaneous T-cell lymphoma
  • HIV
  • AIDS
  • risk
  • survival
  • surveillance epidemiology and end results (SEER) program

Statistics from Altmetric.com

Footnotes

  • Contributors RL: guarantor of integrity of the entire study and manuscript review. JW: study concepts. CH: definition of intellectual content. XL and TZ: study design. NZ: literature research. XD: data acquisition. HD: statistical analysis. BD and GG: manuscript editing. HG: manuscript preparation. QB: study concepts. XC: manuscript review. All authors have read and approved the final version to be submitted.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.